- Previous Close
0.1850 - Open
0.1720 - Bid 0.1740 x --
- Ask 0.2180 x --
- Day's Range
0.1720 - 0.1720 - 52 Week Range
0.1300 - 0.3820 - Volume
300 - Avg. Volume
8 - Market Cap (intraday)
41.477M - Beta (5Y Monthly) 1.32
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0600 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso for chemotherapy induced nausea and vomiting. It also develops SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-04, which is in preclinical trial development for the treatment of colorectal cancer. The company was founded in 2006 and is based in Tokyo, Japan.
www.solasia.co.jp23
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 9SO.F
View MorePerformance Overview: 9SO.F
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9SO.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9SO.F
View MoreValuation Measures
Market Cap
44.61M
Enterprise Value
39.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.76
Price/Book (mrq)
5.62
Enterprise Value/Revenue
20.05
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-67.88%
Return on Equity (ttm)
-128.08%
Revenue (ttm)
316M
Net Income Avi to Common (ttm)
-1.94B
Diluted EPS (ttm)
-0.0600
Balance Sheet and Cash Flow
Total Cash (mrq)
886M
Total Debt/Equity (mrq)
2.16%
Levered Free Cash Flow (ttm)
-1.25B